文献速递肾移植

肾移植受者中第一波与第二波COVID-19疫情期间死亡率无差异

Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2022-09-21

法国2020年两波COVID-19疫情期间共957例肾移植受者住院,第一波359例与第二波598例比较,基线合并症相似,但第二波抗代谢药和钙调神经磷酸酶抑制剂撤减更少、大剂量糖皮质激素使用翻倍,60天死亡率无统计学差异(25.3% vs 23.9%,Log Rank P=0.48)。

要点

  • 两波疫情肾移植受者60天死亡率无统计学差异(25.3% vs 23.9%,Log Rank P=0.48)。
  • 第二波抗代谢药撤减(73.7% vs 58.4%,P<0.001)和钙调神经磷酸酶抑制剂撤减(32.1% vs 16.6%,P<0.001)均较第一波减少。
  • 第二波大剂量糖皮质激素使用较第一波翻倍(19.5% vs 41.6%,P<0.001)。

核心结论

  • 2020年治疗趋势的变化未降低肾移植受者COVID-19相关死亡率。
  • 数据间接支持疫苗接种和中和性单克隆抗SARS-CoV-2抗体对保护肾移植受者免于重症COVID-19的重要性。

研究设计与样本

  • 法国前瞻性收集2020年住院COVID-19的957例肾移植受者数据至法国实体器官移植COVID登记处。
  • 比较第一波诊断的359例与第二波诊断的598例肾移植受者的表现、管理和结局。

主要发现

  • 两波肾移植受者基线合并症相似。
  • 第二波抗代谢药撤减较第一波减少(73.7% vs 58.4%,P<0.001)。
  • 第二波钙调神经磷酸酶抑制剂撤减较第一波减少(32.1% vs 16.6%,P<0.001)。
  • 第一波常用羟氯喹(21.7%)和阿奇霉素(30.9%),第二波几乎弃用。
  • 第二波大剂量糖皮质激素使用较第一波翻倍(19.5% vs 41.6%,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: SARS-CoV-2 pandemic evolved in 2 consecutive waves during 2020. Improvements in the management of COVID-19 led to a reduction in mortality rates among hospitalized patients during the second wave. Whether this progress benefited kidney transplant recipients (KTRs), a population particularly vulnerable to severe COVID-19, remained unclear. METHODS: In France, 957 KTRs were hospitalized for COVID-19 in 2020 and their data were prospectively collected into the French Solid Organ Transplant (SOT) COVID registry. The presentation, management, and outcomes of the 359 KTRs diagnosed during the first wave were compared to those of the 598 of the second wave. RESULTS: Baseline comorbidities were similar between KTRs of the 2 waves. Maintenance immunosuppression was reduced in most patients but withdrawal of antimetabolite (73.7% vs. 58.4%, P < 0.001) or calcineurin inhibitor (32.1% vs. 16.6%, P < 0.001) was less frequent during the second wave. Hydroxychloroquine and azithromycin that were commonly used during the first wave (21.7% and 30.9%, respectively) but were almost abandoned during the second wave. In contrast, the use of high dose corticosteroids doubled (19.5% vs. 41.6%, P < 0.001). Despite these changing trends in COVID-19 management, 60-day mortality was not statistically different between the 2 waves (25.3% vs. 23.9%; Log Rank, P = 0.48) and COVID-19 hospitalization period was not associated with death due to COVID-19 in multivariate analysis (Hazard ratio 0.89, 95% confidence interval 0.67-1.17, P = 0.4). CONCLUSION: We conclude that changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality among KTRs. Our data indirectly support the importance of vaccination and neutralizing monoclonal anti-SARS-CoV-2 antibodies to protect KTRS from severe COVID-19.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Berger B, Hazzan M, Kamar N, et al. Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients. Kidney Int Rep. 2022. PMID: 36159445. doi:10.1016/j.ekir.2022.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。